Published in final edited form as:

Nature. 2007 October 18; 449(7164): 919–922. doi:10.1038/nature06205.

Interferon modulation of cellular microRNAs as an antiviral mechanism

Irene M. Pedersen¹, Guofeng Cheng³, Stefan Wieland³, Stefano Volinia⁴, Carlo M. Croce⁴, Francis V. Chisari³, and Michael David^{1,2}

¹Department of Molecular Biology, Division of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA.

²Moore's Cancer Center, University of California San Diego, La Jolla, California 92093, USA.

³Division of Experimental Pathology, The Scripps Research Institute, La Jolla, California 92037, USA.

⁴Department of Molecular Virology, Immunology & Medical Genetics, Ohio State University, Columbus, Ohio 43210, USA.

Abstract

RNA interference through non-coding microRNAs (miRNAs) represents a vital component of the innate antiviral immune response in plants and invertebrate animals; however, a role for cellular miRNAs in the defence against viral infection in mammalian organisms has thus far remained elusive¹. Here we show that interferon beta (IFN β) rapidly modulates the expression of numerous cellular miRNAs, and that eight of these IFN β -induced miRNAs have sequence-predicted targets within the hepatitis C virus (HCV) genomic RNA. The introduction of synthetic miRNA-mimics corresponding to these IFN β -induced miRNAs reproduces the antiviral effects of IFN β on HCV replication and infection, whereas neutralization of these antiviral miRNAs with anti-miRNAs reduces the antiviral effects of IFN β against HCV. In addition, we demonstrate that IFN β treatment leads to a significant reduction in the expression of the liver-specific miR-122, an miRNA that has been previously shown to be essential for HCV replication². Therefore, our findings strongly support the notion that mammalian organisms too, through the interferon system, use cellular miRNAs to combat viral infections.

miRNAs are a class of small non-coding RNA molecules that function through post-transcriptional regulation of gene expression by a process termed RNA interference (RNAi). Over 500 miRNA-encoding genes, which seem to be exclusively transcribed by RNA polymerase II, have been identified in mammals. These primary microRNAs are processed by the enzymes Drosha/DGCR8/RNASEN into hairpin-loop-containing pre-miRNAs, which are then subject to nuclear export via exportin 5. Further enzymatic processing of the pre-miRNAs by Dicer leads to a mature miRNA duplex that is loaded into the RNA-induced silencing complex (RISC), in which the miRNA guides RISC to complementary messenger RNAs. On the basis of the degree of homology between the miRNA and the mRNA, RISC can inhibit

© 2007 Nature Publishing Group

Correspondence and requests for materials should be addressed to M.D. (midavid@ucsd.edu).

Author Contributions G.C. and S.W. contributed equally to this work.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Author Information Reprints and permissions information is available at www.nature.com/reprints.

mRNA function by either promoting its cleavage or by inhibiting its translation^{3,4}. Particularly, the sequence complementarity in the 6–8 base pair ‘seed region’ at the 5’ end of the miRNA—mRNA heteroduplex seems to determine the specificity of miRNA—targetRNA interactions⁵.

RNAi-mediated targeting of viral RNAs was first recognized in plants as an antiviral defence mechanism, but it is now apparent that invertebrates also use RNAi to combat viral infection^{1,6,7}. However, thus far, no evidence has been presented in support of a protective RNAi-based antiviral response in mammalian cells. Rather, the hypothesis has been proposed that “the extremely potent interferon system has displaced RNAi as the key defence against virus infection in mammalian cells”¹. Indeed, several type I interferon (IFN α/β)-regulated gene products such as protein kinase R, the 2’-5’ OA synthase/RNase L system, the adenosine deaminase ADAR1 or the Mx GTPases are important contributors to the antiviral properties of these cytokines^{8,9}. However, the possibility that IFN α/β might induce cellular miRNAs that target viral transcripts and thereby use RNAi as part of their arsenal against invading viruses has been left unexplored. To test whether IFN α/β could alter the expression of cellular miRNAs, we used microarray technology to analyse RNA derived from IFN α/β - or IFN γ -stimulated cells. This initial screening effort identified ~30 miRNAs, the expression levels of which were increased or attenuated in response to IFN α/β or IFN γ . Because we were interested in determining whether these miRNAs could potentially contribute to the antiviral effects of interferons, we performed sequence complementarity analysis of these miRNAs against viral transcripts or viral genomic RNAs with an initial focus on the crucial seed sequence. This approach revealed promising matches among several viruses, most of which harbour an RNA-based genome. Specifically, eight of the IFN β -induced miRNAs (miR-1, miR-30, miR-128, miR-196, miR-296, miR-351, miR-431 and miR-448) displayed nearly perfect complementarity in their seed sequences with hepatitis C virus (HCV) RNA genomes. This finding was rather intriguing considering that IFN α and IFN β are the most common treatment regimen for HCV infection^{10,11}. Interestingly, a similar analysis of the hepatitis B virus (a DNA virus) yielded no significant matches.

HCV is the sole member of the hepacivirus genus of the Flaviviridae family, and is represented by six major genotypes. The virion contains a 9.6 kb single-stranded RNA genome of positive polarity, with highly invariant 5’ and 3’ untranslated regions^{12,13}. After virus entry into the host cell, the viral genome is uncoated and serves as a template for the translation of a single polyprotein, which is subsequently processed by host and viral proteases. The non-structural viral proteins then initiate the synthesis of a negative-strand RNA, which serves as a replication template for the generation of new positive-strand viral genomes^{12,13}. Sequence alignment of the six HCV genotypes illustrated that the putative miRNA target sites for the IFN β -induced miRNAs are located in areas strictly conserved among all HCV genotypes (see examples in Supplementary Fig. 1a) as well as in regions that differ between the genotypes such that high seed-sequence complementarity occurs only with selected HCV genotypes (see examples in Supplementary Fig. 1b).

To verify our microarray studies we analysed miRNA induction in response to IFN β in the human hepatoma cell line Huh7, as well as in freshly isolated primary murine hepatocytes by quantitative PCR (qPCR). As shown in Fig. 1a, b, IFN β treatment resulted in a similar induction of the prospective antiviral miRNAs in both cell types to that observed in ISG54, a well-characterized IFN α/β -regulated gene¹⁴. Two miRNAs (miR-125 and miR-142) that were found IFN β -unresponsive in the microarray analysis were included as negative controls. We next performed kinetic, as well as dose—response, analyses of the induction of miRNAs by IFN β . Time course analysis revealed that induction of miR-1 and miR-196 occurs very rapidly, with peak concentrations within 30 min, and thus even precedes the upregulation of ISG54 (Fig. 1c). In a similar manner to ISG54 induction, upregulation of miR-1 and miR-196 followed

a classical dose—response curve between 1 and 1,000 U ml⁻¹ IFN β (Fig. 1d), and could be blocked by actinomycin D (data not shown), indicating that the increased levels of miRNAs are the result of transcriptional induction.

miR-122 is specifically expressed in the liver, and previous studies using anti-miRNAs elegantly demonstrated that miR-122, and consequently Dicer¹⁵, are essential for HCV replication². We therefore tested whether miR-122 was also subject to regulation by IFN β . As shown in Fig. 1e, IFN β -stimulation of Huh7 cells resulted in a transient, but pronounced (~80%) down-modulation of miR-122. In a similar manner to miRNA induction, 100 U ml⁻¹ IFN β induced maximal attenuation of miR-122 expression, and no additional effect was observed with increased IFN β concentrations (Fig. 1e).

To evaluate whether the eight IFN β -induced miRNAs with sequence matches in the HCV genome are indeed capable of inhibiting HCV replication, we transfected synthetic miRNA-mimics corresponding to these miRNAs into Huh-7 cells that harbour an autonomously replicating, dicistronic full-length HCV replicon^{16,17}. An anti-miRNA against miR-122 served as a positive control, because it had previously been shown to significantly reduce the abundance of replicon RNA in this system². As expected, non-specific control miRNAs (individually or combined) or anti-miRNA oligos did not alter the amounts of HCV replicon RNA, whereas introduction of anti-miR-122 resulted in a ~70% reduction in viral RNA levels, as previously reported (Fig. 2a). Transfection of the eight candidate miRNAs individually revealed that miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448 were indeed able to substantially attenuate viral replication, whereas miRNAs miR-1, miR-30 and miR-128 were without effect (Fig. 2a). Transfection of a mixture of the five functional miRNA-mimics yielded a >80% reduction in viral RNA load. As IFN β induces miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448 but downregulates miR-122, we decided to imitate this cellular response by transfecting the mix of miRNA-mimics in combination with anti-miR-122. Indeed, a small, but reproducible additive inhibitory effect on HCV replication was observed that was similar in efficacy to treatment of the cells with IFN β (Fig. 2a). Virtually identical results were obtained when Huh7 cells were infected with live JFH1 HCV and either viral RNA levels (Fig. 2b) or viral foci formation (Supplementary Fig. 2) were analysed, further corroborating the fact that the IFN β -induced alterations in the miRNA expression profile endow the cells with a pronounced antiviral state.

To investigate whether these anti-viral miRNAs are targeting the HCV genome rather than inducing a non-specific antiviral state through alteration of cellular gene expression, we took advantage of the fact that the J6CF HCV molecular clone has single-nucleotide variations in the predicted target seed sequences for miR-196 and miR-448 as opposed to JFH1 (Fig. 3a). As J6CF is non-infectious *in vitro*, we employed an infection-competent J6CF/JFH1 chimaeric virus that carried the 'mutant' miR-448 and miR-196 target sites (chimaera J6/JFH) (Fig. 3a). As anticipated, miR-196 was effective against JFH1, but not against J6/JFH, which contained the 'mutant' target site. Similarly, miR-448 only inhibited the replication of JFH1 containing the 'correct' target site, but was ineffective against J6/JFH (Fig. 3b). Introduction of a compensatory single nucleotide change into miR-196 and miR-448 (designated miR-196* and miR-448*) to match their seed sequence to J6/JFH yielded a reversed efficacy profile compared to the wild-type miRNAs when they were tested against the two viruses. As such, both miR-196* and miR-448* were unable to subdue replication of JFH1, but clearly inhibited replication of J6/JFH (Fig. 3b). Together, these results suggest that at least miR-196 and miR-448 are directly targeting the HCV genomic RNA.

Although the above described experiments demonstrate that IFN β -induced miRNAs, in conjunction with the downregulation of miR-122, are sufficient to induce an antiviral state, the question remained whether this modulation of cellular miRNA levels was necessary for

IFN β to prevent HCV replication. To this end, we decided to counteract the IFN β -elicited changes in miRNA expression by transfecting anti-miRNAs against miRNAs miR-196, miR-296, miR-351, miR-431 and miR-448, with and without the inclusion of an miR-122 mimic. IFN β treatment leads to a >90% reduction in the amount of viral HCV replicon RNA and this inhibition is unaffected by transfected non-specific control anti-miRNAs. As shown in Fig. 4, introduction of the anti-miRNA mix, or of the miR-122 mimic separately, attenuated the IFN β effect to ~75% inhibition. Co-transfection of the anti-miRNA mix and the miR-122 mimic further reduced the efficacy of IFN β to ~50%, indicating that modulation of the expression levels of the identified miRNAs has an important, albeit not exclusive, role in the antiviral effects of IFN β against HCV. It remains to be determined whether alterations in the expression levels of the identified cellular miRNAs account for only a part of the antiviral response, or if additional unidentified miRNAs that have not been 'neutralized' by anti-miRNAs mediate the remaining antiviral IFN β effects.

In summary, our results demonstrate that IFN α/β upregulates several cellular miRNAs that are capable of inhibiting HCV replication and infection. In addition, downregulation of miR-122 in response to IFN β further contributes to the antiviral effects of this cytokine. These findings not only offer a new model of the host defence mechanisms that exist in mammalian cells, but also add a new component to the antiviral arsenal employed by interferons. Furthermore, although ample documentation is present in the literature for the developmentally regulated or tissue-specific expression of miRNAs and their dysregulation in malignant cells^{18,19}, little evidence existed for a direct and immediate transcriptional regulation of miRNAs by an endogenous ligand such as a cytokine or growth factor. Our results provide some of the first evidence for rapid changes in cellular miRNA levels in response to ligand stimulation. During the preparation of this manuscript, it was reported that IFN β induced upregulation of miR-155 (ref. ²⁰), a miRNA with, as of yet, no identified targets. The delayed induction kinetics observed in their studies supports the model that miR-155 upregulation is mediated by TNF α as part of an autocrine response elicited by IFN β , rather than by IFN β itself²⁰. Nevertheless, this study and our present report provide the first examples of rapid modulation of cellular miRNAs as components of the mammalian innate immune response.

METHODS SUMMARY

Cell culture

The human hepatoma-derived cell lines Huh7 and their JFH-1-replicon-containing subclone were maintained in DMEM with 10% FCS/10mM Hepes, penicillin/streptomycin and 2 mM L-glutamine. The JFH-1 full-length genomic replicon construct pFGR-JFH-1 was obtained from T. Wakita²¹. A Huh7 cell clone that stably replicates the full-length genomic HCV RNA was selected and used in these experiments, as described previously²². The Huh7.5.1c2 cell line was derived from curing replicon-containing Huh-7.5.1 cells by interferon treatment. Primary murine hepatocytes (BalbC) were collected after collagenase perfusion of the livers for 30 min at 37 °C.

miRNA array analysis

Microarray analysis of total RNA of interferon-stimulated lymphocytes was performed at the Ohio State University Comprehensive Cancer Center Microarray Shared Resource, as described²³.

RNA extraction

Total RNA was isolated using TriZol according to the manufacturer's instructions.

Real-time PCR

Quantification of HCV genomic RNA was performed using HCV- and β -actin- or GAPDH-specific primers as described¹⁶. Real-time PCR-based quantification of miRNAs was performed using miRNA analysis kits specific for each individual miRNA (Applied Biosystems), according to the manufacturers instructions.

METHODS

Transfection of miRNA mimics and anti-miRNAs into Huh7 or Huh7 replicon cells

When JFH1-replicon-containing Huh7 cells (70% confluent) were used for transfection experiments, constant total amounts of miRNA mimics or anti-miRNAs (Dharmacon and Applied Biosystems, respectively) were combined with Mirus transfection reagent (Mirus Bio/Fisher Scientific) according to the manufacturers instructions and added to the cells (transfection efficiency >90%). Where indicated, IFN β (DBL Biomedical Laboratories) was added to the cultures after 8 h, and cells were harvested 48 h post transfection. Viral replication was determined by real-time PCR analysis of viral genomic RNA. Similarly, for experiments using infectious HCV, Huh7 cells were transfected with miRNAs and anti-miRNAs, as described above. HCV infection (multiplicity of infection = 0.05) was performed 8 h post transfection, and IFN β was added where indicated to the cultures at the same time. Cells were harvested at the indicated time points during the phase of exponential viral RNA amplification, and viral replication was determined by real-time PCR analysis of viral genomic RNA, or by determination of the number and size of viral foci after 72 h.

J6CF—JFH1 chimaeric HCV genomes

Recombinant PCR was used to replace the J6CF NS5B-3' UTR region in pCV-J6CF²⁴ with the corresponding sequences from JFH-1 present in pUC-vJFH²⁵. First, using primers XbaJFH (GATTACGCCAAGCTTGCATGCCTGCAG), and NS5Bup (CTCCATGTCATACTCCTGGACCGGGGCTC) and primers NS5Blo (GAGCCCCGGTCCAGGAGTATGACATGGAG) and XhoJ6CF (AGGTTCCATCTCTTCCATGCCCCCCTCG) the NS5B-3' UTR region of JFH-1 and an NS5A-NS5B fragment containing a unique *XhoI* restriction site from J6CF were amplified, respectively. The two PCR products were mutually extended and amplified using the primers XhoJ6CF and XbaJFH, and the resultant PCR product was cloned into pGEM-Teasy (Invitrogen) yielding pTe-J6/JFH, and the insert was verified by DNA sequencing. Finally, the *XhoI* to *XbaI* fragment in pCV-J6CF was replaced by the 2.1-kb *XhoI/XbaI* fragment excised from pTe-J6/JFH, yielding pCV-J6CF/JFHNS5B3'UTR containing the J6/JFH chimaeric HCV genome with the NS5B-3' UTR of J6CF replaced by the corresponding sequences from JFH-1. A similar recombinant PCR approach was used to replicate the J6CF—JFH-1 chimaeric HCV genome Jc1²⁶ by replacing the corresponding JFH-1 core-NS2 region in pUC-vJFH with the corresponding sequences from J6CF to yield the plasmid pUC-vJc1. Infectious JFH-1 and chimaeric viruses were produced by transfection of *in vitro* synthesized genomic HCV RNA into Huh-7.5.1 cells and virus stocks containing 10^4 – 10^5 focus forming units per ml (f.f.u. ml⁻¹) were prepared as described previously²⁷.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank G. Calin (OSU) for help with the microarray studies, D. Burton (TSRI) for E2-antibodies, and J. Zhong (TSRI) for many discussions. This work was supported by the NIH (I.M.P.), a private donation from C. Evans to F.V.C, and the NIH and UCSD Academic Senate Funding (M.D.).

References

1. Cullen BR. Is RNA interference involved in intrinsic antiviral immunity in mammals? *Nature Immunol* 2006;7:563–567. [PubMed: 16715068]
2. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. *Science* 2005;309:1577–1581. [PubMed: 16141076]
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281–297. [PubMed: 14744438]
4. Ambros V. The functions of animal microRNAs. *Nature* 2004;431:350–355. [PubMed: 15372042]
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005;120:15–20. [PubMed: 15652477]
6. Zamore PD. Plant RNAi: How a viral silencing suppressor inactivates siRNA. *Curr. Biol* 2004;14:R198–R200. [PubMed: 15028237]
7. Baulcombe D. RNA silencing in plants. *Nature* 2004;431:356–363. [PubMed: 15372043]
8. Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. *Nature Rev. Immunol* 2002;2:675–687. [PubMed: 12209136]
9. Samuel CE. Antiviral actions of interferons. *Clin. Microbiol. Rev* 2001;14:778–809. [PubMed: 11585785]
10. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann. Intern. Med* 2000;132:296–305. [PubMed: 10681285]
11. Lauer GM, Walker BD. Hepatitis C virus infection. *N. Engl. J. Med* 2001;345:41–52. [PubMed: 11439948]
12. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. *J. Virol* 2005;79:9369–9380. [PubMed: 16014900]
13. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nature Rev. Immunol* 2005;5:215–229. [PubMed: 15738952]
14. Larner AC, et al. Transcriptional induction of two genes in human cells by beta interferon. *Proc. Natl Acad. Sci. USA* 1984;81:6733–6737. [PubMed: 6436820]
15. Randall G, et al. Cellular cofactors affecting hepatitis C virus infection and replication. *Proc. Natl Acad. Sci. USA* 2007;104:12884–12889. [PubMed: 17616579]
16. Zhong J, et al. Robust hepatitis C virus infection in vitro. *Proc. Natl Acad. Sci. USA* 2005;102:9294–9299. [PubMed: 15939869]
17. Moradpour D, et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. *J. Virol* 2004;78:7400–7409. [PubMed: 15220413]
18. Calin GA, Croce CM. MicroRNA—cancer connection: the beginning of a new tale. *Cancer Res* 2006;66:7390–7394. [PubMed: 16885332]
19. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nature Rev. Cancer* 2006;6:857–866. [PubMed: 17060945]
20. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc. Natl Acad. Sci. USA* 2007;104:1604–1609. [PubMed: 17242365]
21. Kato T, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology* 2003;125:1808–1817. [PubMed: 14724833]
22. Cheng G, Zhong J, Chisari FV. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. *Proc. Natl Acad. Sci. USA* 2006;103:8499–8504. [PubMed: 16707574]

23. Liu CG, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. *Proc. Natl Acad. Sci. USA* 2004;101:9740–9744. [PubMed: 15210942]
24. Yanagi M, Purcell RH, Emerson SU, Bukh J. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. *Virology* 1999;262:250–263. [PubMed: 10489358]
25. Wakita T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nature Med* 2005;11:791–796. [PubMed: 15951748]
26. Pietschmann T, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proc. Natl Acad. Sci. USA* 2006;103:7408–7413. [PubMed: 16651538]
27. Zhong J, et al. Robust hepatitis C virus infection *in vitro*. *Proc. Natl Acad. Sci. USA* 2005;102:9294–9299. [PubMed: 15939869]

Figure 1. Regulation of miRNA expression by IFN β in Huh7 cells and primary hepatocytes

a, b, Huh7 cells (**a**) or primary hepatocytes (**b**) were stimulated with 100 U ml⁻¹ IFN β for 2 h, and the indicated miRNAs were quantified by qPCR. ISG54 induction is shown for comparison. **c**, Time course of miRNA induction by IFN β : Huh7 cells were stimulated with 100 U ml⁻¹ IFN β for the indicated times, and miR-1, miR-196 or ISG54 expression was quantified by qPCR. **d**, Dose—response analysis of miRNA induction by IFN β : Huh7 cells were stimulated with the indicated doses of IFN β for 2 h, and miR-1, miR-196 or ISG54 expression was quantified by qPCR. **e**, Time course and dose—response analysis of miR-122 downregulation by IFN β : Huh7 cells were stimulated as described in **c** and **d**, and miR-122 was quantified by qPCR. Error bars, means $\pm$ s.d. of at least four independent experiments.

Figure 2. IFN β -induced miRNAs display anti-viral activity against HCV

a, JFH1-replicon-containing Huh7 cells were transfected with single non-specific miRNA-mimics (miR-ctrl), a pool of control miRNAs (miR-ctrl(mix5)) or anti-miRNAs (anti-miR-ctrl), or specific miRNA-mimics corresponding to the eight IFN β -induced miRNAs, or specific anti-miRNAs. In addition, a combination of the five miRNAs that displayed anti-viral activity individually was used (miR-mix5) with or without anti-miR-122, as indicated, and HCV RNA was quantified by qPCR after 48 h. **b**, Same as **a**, except Huh7 cells were infected with live JFH-1 virus for 48 h (error bars, means $\pm$ s.d. of at least four independent experiments; *P* values are from paired Student's *t*-tests).

Figure 3. IFN β -induced miRNAs directly target viral genomic RNA

a, b, An infectious chimaeric virus was constructed from JFH1 and J6CF as shown in **a**; the numbers in brackets indicate the location in the virion (nucleotides) that the miRNA binds. The Huh7-cell subclone Huh7.5.1c2 was transfected with either miR-196 or miR-448, or with the mutant miR-196* and miR-448* harbouring a compensatory mutation in the seed sequence as outlined in **a**. Transfected Huh7.5.1c2 cells were infected with JFH1(D183) (ref. ²³) or chimaeric J6/JFH, and HCV RNA was quantified by qPCR after 24 or 60 h post infection, respectively, during the phase of exponential viral RNA amplification, to accommodate the difference in replication kinetics between the two viruses (error bars, means $\pm$ s.e.m. of 8 independent experiments; *P* values are from paired Student's *t*-tests).

Figure 4. IFN β -induced miRNAs mediate anti-viral IFN β responses against HCV

JFH1-replicon-containing Huh7 cells were transfected with non-specific miRNA-mimics (miR-ctrl), or non-specific anti-miRNAs (anti-miR-ctrl), or a pool of anti-miRNAs (anti-miR-ctrl(5)), or a combination of anti-miRNA complementary to the five IFN β -induced miRNAs and with potent anti-viral effect (anti-miRNA-mix5), and/or with specific miRNAs and anti-miRNAs, as indicated, before stimulation with IFN β for 48 h. HCV RNA was quantified by qPCR (means $\pm$ s.d. of at least four independent experiments; *P* values are from paired Student's *t*-tests).